Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MPO | P05164 | 3/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435339 | 0.90 | MTNR1A (0.61) | MTNR1AMTNR1BCA2MAPTMPO | |
| SCHEMBL8648779 | 0.84 | MTNR1A (0.58) | MTNR1AMTNR1BCA2MAPTMPO | |
| SCHEMBL5234280 | 0.84 | MTNR1A (0.55) | MTNR1AMTNR1BCA2MAPTMPO | |
| SCHEMBL6985740 | 0.84 | MTNR1A (0.55) | MTNR1AMTNR1BCA2MAPTMPO | |
| SCHEMBL6003503 | 0.83 | MTNR1A (0.60) | MTNR1AMTNR1BCA2MAPTCYP2A6 | |
| SCHEMBL2094883 | 0.81 | MTNR1A (0.52) | MTNR1AMTNR1BCA2MAPTMPO | |
| SCHEMBL14155103 | 0.81 | MTNR1A (0.45) | MTNR1AMTNR1BCA2TYRCYP2A6 | |
| SCHEMBL8435709 | 0.81 | CYP2A6 (0.61) | MTNR1ACA2MAPTCYP2A6 | |
| SCHEMBL8586113 | 0.80 | MTNR1A (0.57) | MTNR1AMTNR1BCA2MAPTMPO | |
| SCHEMBL27628031 | 0.80 | MTNR1A (0.57) | MTNR1AMTNR1BCA2MAPTCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | MTNR1A 77/4885MTNR1B 79/4885CA2 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.